GENFIT: ANNOUNCES ITS FINANCIAL CALENDAR FOR 2019
21 Janvier 2019 - 05:47PM
GENFIT: ANNOUNCES ITS FINANCIAL
CALENDAR FOR 2019
Lille (France);
Cambridge (Massachusetts, United States) - January 21, 2019
-GENFIT (Euronext: GNFT), a late-stage biopharmaceutical
company dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases, today announces its provisional financial calendar for
2019, which is set as follows:
February 4, 2019: Publication of
Full Year 2018 financial statements
The 2018
Registration Document (« Document de Référence 2018 »)
and Annual Financial Report (included in the Registration Document)
will be made public by the end of April 2019
April 30, 2019: Publication of
revenue and cash position at March 31, 2019
June 13, 2019: Annual Shareholders
Meeting in Lille
September 30, 2019: Publication of
the Half Year 2019 financial statements
October 30, 2019: Publication of
revenue and cash position at September 30, 2019
About
GENFIT
GENFIT is a biopharmaceutical
company focused on discovering and developing drug candidates and
diagnostic solutions targeting liver diseases, in particular those
of metabolic origin, and hepatobiliary diseases. GENFIT
concentrates its R&D efforts in areas of high unmet medical
needs corresponding to a lack of approved treatments. GENFIT's lead
proprietary compound, elafibranor, is a drug candidate currently
being evaluated in one of the most advanced Phase 3 studies
worldwide ("RESOLVE-IT") in nonalcoholic steatohepatitis (NASH),
considered by regulatory authorities as a medical emergency because
it is silent, with potentially severe consequences, and with a
prevalence on the rise. Elafibranor has also obtained positive
results in a Phase 2 clinical trial in Primary Biliary Cholangitis
(PBC), a chronic liver disease. As part of its comprehensive
approach to clinical management of NASH patients, GENFIT is
conducting an ambitious discovery and development program aimed at
providing patients and physicians with a blood-based test for the
diagnosis of NASH, i.e. non-invasive and easy-to-access. With
facilities in Lille and Paris, France, and Cambridge, MA (USA), the
Company has approximately 150 employees. GENFIT is a public company
listed in compartment B of Euronext's regulated market in Paris
(Euronext: GNFT - ISIN: FR0004163111). www.genfit.com
GENFIT FORWARD
LOOKING STATEMENT/DISCLAIMER
This press release contains
certain forward-looking statements. Although the Company believes
its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those expressed in, or implied or projected by, the
forward-looking statements. These risks and uncertainties include,
among other things, the uncertainties inherent in research and
development, including related to safety, biomarkers, progression
of, and results from, its ongoing and planned clinical trials,
including its RESOLVE-IT Phase 3 trial, review and approvals by
regulatory authorities, such as the FDA or the EMA, of its drug and
diagnostic candidates, the success of any in-licensing strategies,
the Company's continued ability to raise capital to fund its
development, as well as those discussed or identified in the
Company's public filings with the AMF, including those listed in
Section 4 "Main Risks and Uncertainties" of the Company's 2017
Registration Document registered with the French Autorité des
Marchés Financiers on April 27, 2018 under n° R.18-032, which is
available on GENFIT's website (www.genfit.com) and on the website
of the AMF (www.amf-france.org) and as updated by the 2018 Half
Year Business and Financial Report and available on the Investors
page of GENFIT's website. Other than as required by applicable law,
the Company does not undertake any obligation to update or revise
any forward-looking information or statements. This press release
and the information contained herein do not constitute an offer to
sell or a solicitation of an offer to buy or subscribe to shares in
GENFIT in any country. This press release has been prepared in both
French and English. In the event of any differences between the two
texts, the French language version shall supersede.
genfit
CONTACT
Naomi EICHENBAUM - Investor
Relations | Tel: +1 (617) 714 5252 | investors@genfit.com
Hélène LAVIN - Media & Press
Relations | Tel: +333 2016 4000 | helene.lavin@genfit.com
GENFIT | 885
Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 |
www.genfit.com
01.21.2019 - 2019 Financial
Calendar
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GENFIT via Globenewswire
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024